Investigating CAR T-Cell Therapy Wait Time and High-Risk Disease Definitions in Myeloma With Samer Al Hadidi, MD, MS, FACP
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Investigating CAR T Wait Time and High-Risk Myeloma Definitions With Samer Al Hadidi, MD, MS, FACP At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Samer Al Hadidi, Assistant Professor at the University of Arkansas, sat down with Oncology Data Advisor to discuss the multiple myeloma research that he presented. Dr. Al Hadidi elaborates on his studies regarding the wait list for patients who are eligible to receive chimeric antigen receptor (CAR) T-cell therapy and the variability of definitions of high-risk disease in myeloma clinical trials.  
Exploring the Results of the SUNLIGHT Trial in Metastatic Colorectal Cancer With Josep Tabernero, MD, PhD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Exploring Results of the SUNLIGHT Trial in Metastatic Colorectal Cancer: Josep Tabernero, MD, PhD At the recent American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancer Symposium, Dr. Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology, presented results of the phase 3 SUNLIGHT trial of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer. In this interview, Dr. Tabernero further elaborates on the significance of this treatment combination and its emerging role in the treatment landscape.  
GLAONS Survey of Oncology Nurses Reveals Knowledge Gap Regarding Novel Treatment Options
Lyn Brook
Practice Patterns
In September 2022, i3 Health conducted a survey of 157 oncology nurses at the Greater Los Angeles Oncology Nursing Society (GLAONS) 6th Annual Oncology Care Summit to assess nurses' familiarity with and desire to understand novel oncology treatment options, including chimeric antigen receptor (CAR) T-cell therapies, cyclin-dependent kinase (CDK)4/6...
Exploring the Results of the SUNLIGHT Trial in Metastatic Colorectal Cancer With Josep Tabernero, MD, PhD
Keira Smith
Expert Analysis
At this weekend's American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancer Symposium, Dr. Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology, presented results of the phase 3 SUNLIGHT trial of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer. In this interview, Dr. Tabernero further elaborates on the significance of this treatment combination and its emerging role in the treatment landscape.  
Additional Advances in Squamous Non–Small Cell Lung Cancer Research and Clinical Trials With Mark Kris, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Additional Advances in Squamous NSCLC Research and Clinical Trials With Mark Kris, MD In 2022, Dr. Mark Kris, the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, served as chair of Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer (NSCLC), a continuing medical education (CME)/nursing continuing professional development (NCPD) activity. A year later, Dr. Kris sat down again with Oncology Data Advisor to share the progress that has occurred in this field and the important considerations to keep in mind when treating patients with squamous NSCLC in 2023.
Pioneering the Field of Stem Cell Biology With Irving Weissman, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Pioneering the Field of Stem Cell Biology With Irving Weissman, MD At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in becoming involved in basic science research.  
Additional Advances in Multiple Myeloma Research and Clinical Trials: With Sarah Holstein, MD, PhD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Additional Advancements in Research: Multiple Myeloma Earlier this year, Dr. Sarah Holstein of the University of Nebraska Medical Center participated in a two-part continuing medical education (CME) activity regarding practice-changing strategies and improved patient outcomes in the treatment of multiple myelom...
Highlights from the San Antonio Breast Cancer Symposium With Jason Mouabbi, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Highlights from the San Antonio Breast Cancer Symposium At the recent San Antonio Breast Cancer Symposium (SABCS), researchers from around the world presented breaking developments in the treatment and care of patients with breast cancer. In this interview, Dr. Jason Mouabbi, an Assistant Professor in the Devel...
Oncology Data Advisor 2022 Year-End Wrap-Up
Keira Smith
Featured Exclusive
Wow! 2022 has been an exciting year of new challenges, amazing successes, and incredible opportunities. And we couldn't have gotten through it all without YOU! Before we wrap up the top stories and new features from OncData this year, we want to take time to thank each and every one of YOU: doctors, nurses, medical staff, and all frontline workers for your continued dedication. You continue to inspire us each and every day. THANK YOU!
Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ With Jason Mouabbi, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobular carcinoma in situ as a poor prognostic marker in invasive lobular carcinoma, which will be prese...
Emphasizing Communication and Expectations for Lung Cancer Side Effects With Blanca Ledezma, MSN, NP
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Emphasizing Communication and Expectations for Lung Cancer Side Effects With Blanca Ledezma, MSN, NP With the advent of targeted therapies in lung cancer, patients are experiencing improved outcomes through personalized medicine. However, education regarding potential toxicity is crucial. In this interview, Blanca Ledezma, MSN, NP, shares the importance of setting up expectations for the side effects of targeted therapies for lung cancer and emphasizing communication with the health care team throughout the course of treatment.  
Highlights from the San Antonio Breast Cancer Symposium With Jason Mouabbi, MD
Lyn Brook
Expert Analysis
At the recent San Antonio Breast Cancer Symposium (SABCS), researchers from around the world presented breaking developments in the treatment and care of patients with breast cancer. In this interview, Dr. Jason Mouabbi, an Assistant Professor in the Development of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, shares...
Predicting Invasive Lobular Carcinoma Prognosis Through Absence of Lobular Carcinoma in Situ With Jason Mouabbi, MD
Keira Smith
Expert Analysis
In this interview, Dr. Jason Mouabbi speaks with Oncology Data Advisor about his research regarding the absence of lobular carcinoma in situ as a poor prognostic marker in invasive lobular carcinoma, which will be presented as a poster at the 2022 San Antonio Breast Cancer Symposium (SABCS).  
Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer With Anne Chiang, MD, PhD, and Henry Park, MD, MPH
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 14% of cases are classified as small cell lung cancer (SCLC). While SCLC is usuall...
An Introduction to Breast Cancer Therapies: A Patient Resource From Samuel Kareff, MD, MPH
Keira Smith
Expert Analysis
Oncology Data Advisor™ · An Introduction to Breast Cancer Therapies: A Patient Resource From Samuel Kareff, MD, MPH In this interview with Oncology Data Advisor, Dr. Samuel Kareff, a Hematology-Oncology Fellow at Sylvester Comprehensive Cancer Center of the University of Miami, provides a comprehensive overview of the current and emerging therapies used in the treatment of breast cancer, serving as a valuable resource to share with patients who may be discussing these options with their oncology team.  
The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker: Part 2
Keira Smith
Expert Analysis
In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can focus on communication, support, relationships, personal reflection, and laughter. In 2016, Janie Metsker, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at St. Luke's Hospital, launched these retreats at her own institution. In this interview with Oncology Data Advisor, Ms. Shockney and Ms. Metsker reflect on the impactful moments that take place during the retreats and their profound significance for the patients who attend.  Watch the first part of Ms. Shockney and Ms. Metsker's conversation here!
Understanding Clonal Hematopoiesis in Hematologic Malignancies With Rahul Banerjee, MD, Jeremy Meier, MD, and Samuel Rubinstein, MD
Keira Smith
Expert Analysis
Dr. Jeremy Meier and Dr. Samuel Rubinstein of the University of North Carolina (UNC) Chapel Hill are the first and senior author, respectively, of a recently published review paper entitled Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma. In this interview for Blood Cancer Awareness Month, Oncology Data Advisor's Editorial Board member Dr. Rahul Banerjee speaks with Dr. Meier and Dr. Rubinstein about their work in this area and the future of clonal hematopoiesis research in hematologic malignancies.
Personalizing Lung Cancer Care Through Biomarkers and Precision Medicine With Blanca Ledezma, MSN, NP
Keira Smith
Expert Analysis
In this interview with Oncology Data Advisor, Blanca Ledezma, MSN, NP, elucidates the current landscape of therapeutically actionable biomarkers in lung cancer and the promising future of precision medicine in this field. In addition, she explains the clinical applications for lung cancer biomarkers in nursing practice, including unique toxicity management and patient education for novel therapies.  
Increasing Expertise for Treatment of Non-Hodgkin Lymphoma
Lyn Brook
Practice Patterns
An educational activity provided by i3 Health has bridged knowledge gaps experienced by nursing professionals and other health care professionals on the topic of treatment strategies for patients with non-Hodgkin lymphoma (NHL). Accounting for 4% of all cancers diagnosed, NHL is one of the most common cancer types in the United States. The American...
Blood Cancer Awareness Month: Exploring Patient-Reported Outcomes With Rahul Banerjee, MD, FACP, and Ajay Major, MD, MBA
Keira Smith
Expert Analysis
Recently, Dr. Rahul Banerjee, Assistant Professor at the University of Washington and Editorial Board member for Oncology Data Advisor, spoke with Dr. Ajay Major, Assistant Professor at the University of Colorado, in a live interview discussion in honor of Blood Cancer Awareness Month. Dr. Banerjee and Dr. Major engaged in a riveting conversation about the role of patient-reported outcomes (PROs) in lymphoma and myeloma, including how to interpret them and how to include them when designing research.  

Copyright © 2022 Oncology Data Advisor. All rights reserved.